We also found that in the combination PD-1 antibody and evodiamine treatment group, tumor-infiltrating CD8+ T cells showed stronger activation phenotypes and more increased IFN-γ, TNFα and Granzyme B (GrzmB) production (Fig. 7f). The gene discussed is PDCD1; the disease is neoplasm.